KANSAS CITY, Mo.--(BUSINESS WIRE)--Teva (NASDAQ:TEVA) today announced the launch of a new, thinner, 29-gauge pre-filled syringe for its multiple sclerosis (MS) treatment, COPAXONE® (glatiramer acetate injection). A recent survey of 562 MS patients found the new thinner needle was significantly preferred by 77 percent of patients over the previous 27-gauge needle.
